Hedge fund mogul Bill Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan, his firm's big bet for 2014.» Read More
Look to your left. Look to your right. At least one of you probably drinks too much, according to the Centers for Disease Control and Prevention.
After drug company Sanofi removed CEO Chris Viehbacher, investors question the future of the company's growth and future.
Funding by the Cystic Fibrosis Foundation to create drugs for the disease creates conflict of interest, reports the New York Times.
The CDC has taken down a website that offered to help American bosses tally financial losses linked to their overweight employees, NBC News reports.
Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.
The deal beats the unsolicited bid last spring of above $50 billion from Valeant, which teamed with Bill Ackman.
Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.
Actavis is nearing a deal to acquire Allergan in a cash and stock deal worth more than $210 per Allergan share, sources tell CNBC.
A major collaboration between Pfizer and several global aid groups is aiming to provide financing to make a new version of an injectable contraceptive, the NYT reports.
NASH, or nonalcoholic steatohepatitis, is a liver disease that may affect as much as 12 percent of the U.S. population, Genfit's Dean Hum said.
Arrowhead Research Chief Executive Chris Anzalone contends the company's hepatitis B therapy, ARC-520, has potential.
Merck hoped to trump Gilead's hepatitis C treatment with its own shorter therapy, but early results show the four-week regimen may not be successful.
Researchers, companies and Wall Street are gathering to gain a sense of bringing potentially multibillion dollar drugs to market.
To fast-track autism research, Google and scientists are using data analytics to find its roots and possible cures.
A start-up has created technology it says can detect a variety of cancers with a device that can be used in a GP's surgery – or even at home.
AbbVie reported strong earnings on demand for its Humira drug and said it could deliver strong long-term growth without another big merger bid.
Gilead Sciences reported Tuesday that sales of its Hepatitis C drug, Sovaldi, fell nearly 20 percent from the prior quarter.
A nasty Wall Street divorce has touched two biotech CEOs and appears to have moved their company stocks down over drug use allegations.
Swiss drugmaker Novartis reported better-than-expected results on Tuesday, as strong sales of new products helped offset the expiration of a key patent.
Amgen's CEO provided an answer to Dan Loeb's recent suggestion that the biotechnology company be split up. In short, he said, it doesn't make sense.
Get the best of CNBC in your inbox